Answers are grounded in this paper and cite their sources.
Biosimilars face significant challenges in assessing their value. The rapid development of this area of t he pharmaceutical industry requires a rethinking of the economic evaluation of drugs and optimization of regulatory procedures.
No takes yet. Share an insight, caveat, or question.
Valeeva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: